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TRANSPLANTATION
Allogeneic chimerism with low-dose irradiation, antigen presensitization, and
costimulator blockade in H-2 mismatched mice
Peter J. Quesenberry, Suju Zhong, Han Wang, and Marc Stewart
We have previously shown that the keys
to high-level nontoxic chimerism in synge-
neic models are stem cell toxic, nonmyelo-
toxic host treatment as provided by 100-
cGy whole-body irradiation and relatively
high levels of marrow stem cells. This
approach was unsuccessful in H-2 mis-
matched B6.SJL to BALB/c marrow trans-
plants, but with tolerization, stable multi-
lineage chimerism was obtained. Ten
million B6.SJL spleen cells were infused
intravenously into BALB/c hosts on day
210 and (MR-1) anti-CD40 ligand mono-
clonal antibody (mAb) injected intraperito-
neally at varying levels on days 210, 27,
23, 0, and 13 and the BALB/c mice irradi-
ated (100 cGy) and infused with 40 million
B6.SJL/H-2 mismatched marrow cells on
day 0. Stable multilineage chimerism at
levels between 30% to 40% was achieved
in the great majority of mice at 1.6 mg
anti-CD40 ligand mAb per injection out to
64 weeks after transplantation, without
graft-versus-host disease. The transplanted
mice were also tolerant of donor B6.SJL,
but not third-party CBA/J skin grafts at 8
to 9 and 39 to 43 weeks after marrow
transplantation. These data provide a
unique model for obtaining stable partial
chimerism in H-2 mismatched mice, which
can be applied to various clinical diseases
of man such as sickle cell anemia, thalasse-
mia, and autoimmune disorders. (Blood.
2001;97:557-564)
© 2001 by The American Society of Hematology
Introduction
Dogma has held that cytotoxic ablative therapy was needed to open
space and allow for marrow stem cell engraftment.1 Reports by a
number of investigators established that engraftment could be
obtained in nonmyeloablated mice, but some dismissed this as not
significant.2-6 We have modeled our initial studies on those of
Brecher and coworkers5 and established that at the stem cell level,
engraftment is quantitatively complete in the absence of any
cytoablative treatment; the final differentiated phenotype of engraft-
ment is determined by the ratio of host/donor stem cells.7-10
Mathematical modeling indicated that the final level of differenti-
ated donor hematopoietic cells in transplanted mice related directly
to the ratio of infused donor marrow cells to total host marrow
cells.11 This relationship holds because the relative numbers of
differentiated donor and host cells in transplanted mice presumably
reflects the relative number of donor and host lymphohematopoi-
etic stem cells.
These data, indicating that engraftment in a syngeneic setting
was determined solely by stem cell competition, were confirmed
by studies in mice subjected to 100-cGy whole-body irradiation
(WBI) and transplanted with varying levels of marrow cells.12 Here
with a male BALB/c to female BALB/c transplant model, engraft-
ment generally correlated inversely with numbers of host engraft-
able stem cells. This level of irradiation proved to be relatively
nonmyelotoxic, but quite stem cell toxic, and high levels of stable
long-term multilineage chimerism could be obtained with lower,
but still relatively high, levels of infused marrow cells.
These studies suggested strategies for creating nontoxic chime-
rism in allogeneic stem cell transplantation using (1) nonmyelo-
toxic, but stem cell toxic, host treatment (100 cGy) and (2)
relatively high levels of donor stem cells. Initial studies with
B6.SJL to BALB/c H-2 incompatible murine marrow transplants,
using 100-cGy host treatment and 40 million infused marrow cells,
failed to show engraftment and indicated that tolerizing approaches
were probably needed.
To initiate an effective T-cell response to antigen, 2 activation
signals are needed. The primary interaction is between the antigen–
major histocompatibility complex (MHC) and the T-cell receptor,
but an interaction between a costimulatory molecule and its
receptor is also necessary. Two major costimulatory pathways
continue to be defined. The B7 (CD80 and CD86) family of
molecules on antigen-presenting cells (APC) binds to T-cell
antigens CD28 and CTLA4,13-16 whereas CD40 molecules on APC
bind to CD40 ligand on T cells.17-21 T cells receiving the MHC–
antigen–T-cell receptor signal in the absence of a costimulatory
signal become anergic or are depleted.22-28 However, cytotoxic T
lymphocytes receiving both activation signals can then expand
clonally and respond to target cells expressing the MHC-antigen
complex. Blocking these costimulator pathways presented attrac-
tive approaches to establishing antigen-specific tolerance. Early
studies showed survival of cardiac allografts29 and xenogeneic islet
grafts in mice30 using CTLA4 Ig inhibition of the B7-CD28
pathway, although other studies indicated that blockade of either
the B7-CD28 or CD40-CD40 ligand pathways alone was insuffi-
cient to permit engraftment of highly immunogenic allografts.31-33
Use of a double blockade of CD40 and CD28 pathways allowed
engraftment of alloantigen MHC-mismatched cardiac and skin
grafts34 and xenogeneic rat to mouse cardiac and skin grafts and pig
skin to mouse grafts.35 Anti-CD40 ligand monoclonal antibody
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(mAb) was found to block acute and chronic graft-versus-host
disease (GVHD) and to decrease alloreactive CD41 thoracic duct
lymphocytes.36,37 Wekerle and colleagues38 reported on costimula-
tor blockade in mice conditioned with 300 cGy total body
irradiation (TBI) and infused with hematopoietic marrow cells.
They found use of CTLA4 Ig or anti-CD40 ligand mAb alone
resulted in transient chimerism, but the use of both agents resulted
in stable long-term hematopoietic chimerism (. 40% and . 8
months). The use of both agents was also effective in prolonging
primate kidney grafts.39
Some investigators had shown that pretreatment with allogeneic
T cells may tolerize and antigen presentation without costimulation
leads to T-cell nonresponsiveness.22-28 These studies focused on
CD28/B7 blockade with CTLA4 Ig. CTLA4 Ig was used in
combination with donor antigen, 100-cGy total-body irradiation,
and immunosuppression with mycophenolate mofetil and cyclospor-
ine to obtain hematopoietic chimerism in dogs.40 Costimulation can
also be prevented by blocking anti-CD40/CD154 interaction and
subsequent up-regulation of B741-43 and anti-CD40 ligand/CD40
blockade with anti-CD40 ligand mAb combined with donor cell
pre-exposure was used to obtain allogeneic murine pancreatic islet
grafts44-46 and xenogeneic rat islet and skin grafts in mice.47,48
We have used spleen cell antigen pre-exposure and concomitant
blockade of the CD40/CD40 ligand pathway combined with
nonmyelotoxic/stem cell toxic host treatment (100 cGy) and high
levels of marrow cells (40 million) in an H-2 mismatched B6.SJL




The B6.SJL(H-2b) and CBA/J(H-2k) mice were obtained from the Jackson
Laboratory (Bar Harbor, ME). BALB/c(H-2d) mice were obtained from
Taconic Farm (Taconic, NY). Mice were certified to be specific pathogen
free, housed in our animal facility, and given ad libitum access to
autoclaved food and acid water. They were maintained in accordance with
local and federal guidelines (Department of Health, Education and Welfare
Publication, National Institutes of Health [NIH] 78-23, 1985). These studies
were approved by the University of Massachusetts Institutional Animal
Care and Use Committee (IACUC) Docket: IACUC approval date 3/22/99.
Animal Welfare assurance number A3306-01. The mice in our facility have
been tested for Sendai virus (SEN), pneumonia virus of mice (PVM),
mouse hepatitis virus (MHV), minute virus of mice (MVM), mouse polio
virus (GD-7), reovirus type 3 (REO-3), Mycoplasma pulmonis (MPUL),
mouse parvovirus (MPV), epizootic diarrhea of infant mice virus (EDIM),
lymphocytic choriomeningitis virus (LCMV), mouse adenovirus FL/K87
(MAD), ectromelia virus (ECTRO), mouse pneumonitis virus (K), and
polyoma virus (POLY). They were all negative for those tests.
Bone marrow transplantation
Normal male B6.SJL mice (age 6-8 weeks, weight 16-18 g) were used as
donors and male BALB/c mice (age 6-8 weeks, weight 16-18 g) as
recipients. B6.SJL marrow cells were flushed from tibia and femurs into
sterile phosphate-buffered saline (PBS) with a syringe and 25-gauge needle.
Sterile cells were resuspended with 5-mL pipettes into a single cell
suspension and passed through a 40 mm cell strainer. Cell number was
counted in crystal violet and 40 3 106 bone marrow cells were injected
intravenously into each recipient (day 0).
Donor cell phenotype analysis after transplantation
(FACS analysis)
Peripheral blood was collected from each transplant mouse by eye bleeding
starting 3 weeks after transplantation. Fifty microliters was used to do
labeling with fluorescein isothiocyanate (FITC)–conjugated CD45.1 (A-20
line, PharMingen, San Diego, CA). Donor cell percentage in recipient was
determined as FITC-positive cells divided by total cell number. B6.SJL
blood was used as positive control, with labeling in the range of 95% to
98%, and BALB/c blood was used as negative control with the range of 1%
to 2%. FITC-conjugated CD3 (clone 17A2), biotin-conjugated CD19 (clone
1D3), and biotin-conjugated Gr-1 (clone RB6-8C5) were used to label the T
cells, B cells, and granulocytes, respectively, when doing the sublineage
analysis of engrafted cell phenotype. Donor cells were labeled with CD45.1
antibody. All antibodies are from PharMingen.
Donor-specific tolerance
Normal male B6.SJL (age 6-8 weeks, weight 16-18 g) spleen cells
(10 3 106) were injected by tail vein 10 days before bone marrow
transplant and anti-CD40 ligand antibody injected intraperitoneally imme-
diately before the injection of B6.SJL spleen cells (day 210) and then on
days 27, 23, 0, and 13 (“standard protocol”).
Murine anti-CD40 ligand mAb production and quantification
The MR-1 hybridoma cell line (gift from Dr Randolph Noelle, Dartmouth
Medical School, Dartmouth, NH) produces murine anti-CD40 ligand mAb.
The isotype of this antibody is Armenian hamster IgG, group 3, k. Briefly,
BALB/c SCID mice (Jackson Laboratory) were primed with 0.5 mL
Pristane (2,6,10.14-tetramethylpentadecane; Sigma Chemical, St Louis,
MO) intraperitoneally. Seven to 10 days after the Pristane priming, 2 3 106
MR-1 cells (viability . 75%) were injected intraperitoneally into each of
the BALB/c SCID mice. Ascites was apparent by 7 to 10 days after cell
injection and was then drained with sterile needles every other day. Freshly
collected ascites was incubated at 37°C for 1 hour, then 4°C overnight.
After centrifugation at 3000 rpm for 30 minutes, supernatant was filtered
through a 0.2-mm filter. Samples were aliquoted and stored at 280°C.
These were thawed immediately before injection into mice.
Enzyme-linked immunosorbent assay (ELISA) was used to quantitate
the amount of Armenian hamster IgG in the ascites. The ELISA plates
(Becton Dickinson, CA) were coated with 100 mL capture antibody (affinity
purified goat anti–Armenian hamster IgG) and incubated at 4°C overnight.
Unknown concentration ascites and commercial anti-CD40 ligand antibody
(PharMingen) were added to appropriate wells after serial dilution for 4°C
overnight. Biotinylated goat antihamster IgG was added to the wells
followed by avidin-horseradish peroxidase at appropriate dilutions. TMB
Peroxidase EIA Substrate Kit (Bio-Rad, Hercules, CA) was used for
detection and plates read at 650 nm. Standard curves were made from the
commercial anti-CD40 ligand antibody preparation and unknown ascites
concentrations calculated based on the standard curves.
Skin graft transplantation
Skin was removed from the abdomen of euthanized murine B6.SJL(H-2b)
or CBA/J(H-2k) donors with chloride hydrate anesthesia, and the underside
was gently scraped with a scalpel to remove fat and muscle. Prepared skin
was placed on sterile filter paper moistened with Hanks balanced salt
solution (HBSS) buffered with HEPES (pH 7.4; Sigma Chemical) and kept
at room temperature until used within 2 hours. The dorsal thoracic surfaces
of anesthetized recipient mice were shaved and washed with 70% ethanol.
A graft bed was prepared with fine scissors by removing an area of
epidermis and dermis down to the level of the intrinsic muscle. Grafts 1.0 to
1.5 cm2 in area were fitted to the prepared bed without suturing and then
covered with Vaseline-impregnated gauze and an adhesive plastic bandage.
After 6 days, the bandage was removed. Skin graft survival was assessed 3
times a week by visual and tactile examination. Rejection was defined as the
first day on which the entire epidermal surface of the graft was necrotic.
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Statistics
The nonparametric Wilcoxon rank-sum test is used for comparison. The
trend test developed by Cuzick was used for testing trend.49 The level
of statistical significance is set at .05 (2-sided). Data are presented as
mean 6 1 SEM.
Results
H-2 mismatched transplant without costimulator blockade
In the initial studies we attempted to apply the strategy of 100-cGy
BALB/c host irradiation with infusion of 40 million B6.SJL
marrow cells. As shown in Figure 1, at 100 cGy, there was
essentially no engraftment. In a few experiments relatively low
levels of engraftment have occurred sporadically, but overall at this
level of irradiation with this number of cells and 100-cGy host
irradiation, marrow is rejected. As shown in Figure 1, stable
long-term chimerism was not achieved until sublethal levels of
single-dose irradiation (400-500 cGy) were delivered to the
BALB/c hosts.
B6.SJL engraftment in C57BL/6 mice
In previous studies using 40 million BALB/c cells into 100-
cGy–treated BALB/c hosts, we have obtained relatively high levels
of chimerism, ordinarily above 60% out to 8 months after marrow
infusion.12 We determined the levels of syngeneic chimerism when
B6.SJL, H-2 compatible marrow cells were infused into C57BL/6
hosts. This combination should be histocompatible. As shown in
Figure 2, levels between 20% and 30% chimerism were obtained.
Twenty-one week engraftment was also determined in marrow,
spleen, thymus, and peripheral blood. Engraftment levels of blood,
spleen, thymus, and marrow were 23.2% 6 9.3%, 25.3% 6 8.2%,
28.4% 6 13.6%, and 14.9% 6 5.3%, respectively. BALB/c and
C57BL/6J mice evidence different results when radiation sensitiv-
ity is assessed.50 LD50/30 values for 4-month-old female BALB/cJ
and C57BL/6J mice were 616 6 12.8 cGy and 705 6 6.2 cGy,
respectively, indicating that BALB/cJ mice were 13% more
sensitive to radiation when this parameter was measured. However,
if endogenous spleen colony survival was assessed, C57BL/6J had
D0 (D0 reduces survival by a factor of 0.37) values of 65 6 4.4 cGy,
whereas BALB/cJ mice gave values of 79.4 6 5.8 cGy, indicating
that C57BL/6J were 18% more sensitive to irradiation when this
parameter was measured. At the most, C57BL/6J are not more than
20% more sensitive to irradiation than BALB/c mice. Thus, the
present results suggest a “BALB/c equivalent” maximum for
C57BL/6J engraftment, under the conditions of these experiments,
of approximately 40%, significantly less than seen with a male
BALB/c to female BALB/c transplantation.
Antigen pre-exposure and costimulator blockade in H-2
mismatched murine marrow transplantation
We evaluated the addition of antigen pre-exposure and costimula-
tor blockade to the model of infusing 40 million H-2 mismatched
B6.SJL cells into 100-cGy–treated BALB/c hosts. Here, as de-
scribed in “Materials and methods,” 10 million B6.SJL spleen cells
were infused by tail vein 10 days prior to transplantation and
varying dose levels of anti-CD40 ligand antibody were given
immediately prior to the spleen cell infusion and thereafter on days
27, 23, 0, and 13. On day 0, 40 million B6.SJL whole marrow
cells were infused into BALB/c hosts, which had received 100 cGy
within 4 hours of marrow infusion. Figure 3 presents long-term
results in experiments evaluating graded doses of antibody in this
model. Here we see that long-term allochimerism at levels ranging
Figure 2. Engraftment of B6.SJL marrow in C57BL/6 hosts. Forty million male
B6.SJL marrow cells were infused into nonirradiated (0 cGy) or irradiated (100 cGy)
C57BL/6 male hosts and percent engraftment in peripheral blood determined out to
21 weeks after transplantation. Data are presented as percentage (%) engraftment
6 1 SEM. There were 5 mice per group and engraftment was evaluated by CD45.1
labeling FACS analysis on individual mice. Values in the 100-cGy group were
significantly different from the 0-cGy group at all time points (P , .05). At 21 weeks,
engraftment was also determined in marrow, spleen, and thymus, along with
peripheral blood. Percent engraftment levels in blood, spleen, thymus, and marrow
were 23.2 6 9.3, 25.3 6 8.2, 28.4 6 13.6 and 14.9 6 5.3, respectively.
Figure 1. Effect of host irradiation on B6.SJL
engraftment into BALB/c hosts. BALB/c recipient
mice were either unirradiated or subjected to 100 to
600 cGy WBI and then infused with 40 million B6.SJL
marrow cells. The percentage (%) donor (CD45.11)
cells in peripheral blood 6 1 SEM are presented out to
21 weeks after transplantation. There were 4 mice per
group at 400 cGy and 500 cGy and 5 mice per group at
all other levels. After 9 weeks the 100-cGy groups
dropped to 4 mice. Values for the 600-cGy group were
significantly different from the 0-, 200-, and 300-cGy
groups at all time points out to 21 weeks (P , .05).
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from 30% to 40% were obtained out to 47 weeks after marrow
infusion, at the 1.6-mg per injection antibody level. If spleen cells
were given with this approach, but marrow was not infused, no
engraftment was seen.
Multilineage engraftment was evaluated at 22 and 35 weeks
after transplantation (Figure 4). In each instance engraftment was
seen in the T-cell, B-cell, and granulocyte lineages. The distribution
of each type was similar to that seen in normal B6.SJL mice,
although donor CD19 percentages were relatively lower in the
transplanted mice. We also evaluated engraftments in marrow,
spleen, blood, and thymus at 50 weeks in selected mice from this
experiment (Table 1). Multiorgan engraftment was seen, but with
relatively lower levels of bone marrow engraftment due to a failure
of the anti-CD45.1 mAb to react with erythroid precursors.
Stable chimerism has now been observed out to 64 weeks in 2
mice given this “standard protocol” (1.6 mg anti-CD40 ligand
antibody) at 29.1% and 29.3%. In a total of 30 mice, using the
“standard protocol” with 1.6 mg of anti-CD40 ligand monoclonal
antibody and 2day 10 spleen cell pre-exposure, evaluated at 9
weeks, the mean marrow engraftment 6 1 SE was 28.9% 6 3%.
Seven of the 30 mice showed no, or very low, levels of engraftment
(up to 3.1%). If the 23 mice showing higher levels of engraftment
were analyzed, the mean engraftment level was 37.4% 6 1.6%.
These values suggest, when compared to engraftment seen with
B6.SJL into C57BL/6 mice, that a relatively high level of engraft-
ment was obtained at the cell level of 40 million donor mar-
row cells in these B6.SJL to BALB/c transplants, using the “stan-
dard protocol.”
We further evaluated whether a spleen cell injection was
required for induction of allochimerism. We also evaluated spleen
cell administration at 27 or 210 days in the same experiments.
Here, as shown in Figure 5, it was clear that omission of antigen
preexposure with spleen cell injection resulted in no (or very low)
chimerism. Alteration between day 7 and 10 had relatively little
effect, but these results indicated that, in the context of this model,
spleen cell infusion was needed to obtain full allochimerism. The
impact of a secondary marrow transplant of 40 million B6.SJL cells
between weeks 12 and 13 was assessed in mice in these experi-
ments (asterisks in Figure 5). There was no augmentation of
engraftment seen in groups I and V to VIII, but the 0 cGy groups
treated with CD40 ligand antibody, and especially with spleen
presensitization, showed an augmentation of engraftment, suggest-
ing that secondary transplantation may be useful in these models.
We next investigated whether altering cell dose would affect
allochimerism. In Figure 6 we show results when 40 million, 80
million, or 120 million marrow cells were infused in the “standard
protocol.” Increasing the number of cells to 80 million significantly
increased allochimerism, whereas there was little further increase
with an increase to 120 million cells. Evaluation of engraftment in
the spleen, thymus, marrow, and blood of 2 mice in the 80 million
and 2 mice in the 120 million cell groups showed multiorgan
engraftment that was relatively similar for all groups except
thymus, which showed higher levels (data not shown) of engraft-
ment, as compared to the other tissues.
The previous data showing an antibody dose-response curve out
to 41 weeks was followed by further escalations of antibody levels
in the “standard protocol.” In Figure 7 we show that increasing
anti-CD40 ligand antibody to 3.2 mg/injection further increased the
level of allochimerism. In separate studies (data not shown) we
have established that 1.6 mg of control hamster IgG used, instead
of anti-CD40 ligand antibody, in the full spleen pre-exposure
costimulator blockade B6.SJL to BALB/c transplant model did not
result in allochimerism. In further studies we have used ELISA to
determine anti-CD40 ligand hamster mAb levels in murine blood.
Levels of antibody remained detectable out to 15 weeks after the
Figure 4. Multilineage engraftment of B6.SJL marrow into 100-cGy–irradiated
BALB/c hosts preexposed to B6.SJL spleen cells and treated with anti-CD40
ligand mAb. Engrafted mice described in Figure 3 were analyzed for multilineage
engraftment by determining the percentage of cells in the host peripheral blood
labeled with both CD45.1 and either CD3 (T cells), CD19 (B cells), or Gr-1
(granulocytes) and analyzed by FACS (see “Materials and methods”) at 22 and 35
weeks after transplantation. Data are presented as mean percentage engraftment of
donor CD3, CD19, or Gr-1 cells 6 SEM. There were 4 to 5 mice per group.
Figure 3. Engraftment of B6.SJL marrow into 100-
cGy irradiated BALB/c hosts pre-exposed to B6.SJL
spleen cells and treated with anti-CD40 ligand (L)
monoclonal antibody (mAb). BALB/c hosts were in-
fused with 10 million B6.SJL spleen cells (SC) on day
210. Immediately before spleen cell infusion and on days
27, 23, 0, and 13 BALB/c hosts were injected with
varying amounts of anti-CD40 ligand (mAb) intraperitone-
ally. These mice were subjected to 100-cGy WBI and
infused with 40 million B6.SJL marrow cells on day 0.
Donor chimerism was determined by staining peripheral
blood cells with CD45.1 antibody and analyzing individual
mice by FACS. Data are expressed as percent engraft-
ment out to 47 weeks after transplantation. There were
initially 5 mice per group. Group I had 4 mice per group
after week 9, and group VI had 4 mice per group after
week 16. At 47 weeks, smaller numbers of mice were in
each group due to the use of mice for other experimental
points. Groups V and VI were statistically different from
groups I, II, and III at all time points, P , .02 and P , .01,
respectively. W indicates weeks.
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initial antibody course, but were undetectable at 38 weeks (Figure
8). Two mice were also tested at 68 weeks and anti-CD40 ligand
antibody was not detected.
Finally, we have tested the presence of antigen-specific toleriza-
tion evaluating acceptance of donor B6.SJL(H-2b) and third-party
CBA/J(H-2k) skin grafts into H-2 mismatched BALB/c mice,
which had been subjected to B6.SJL spleen cell infusions with or
without anti-CD40 ligand antibody blockade. Here B6.SJL marrow
was infused into 100-cGy–treated hosts (the “standard protocol”)
and 8 to 9 and 39 to 43 weeks later BALB/c mice evaluated for
acceptance or rejection of donor or third-party skin grafts. As
shown in Table 2 skin donor grafts in marrow allochimeric mice
were accepted and third-party CBA/J grafts rapidly rejected. Skin
graft acceptance was durable out to 31 weeks. Control transplanted
mice without marrow allochimerism or nontransplanted control
BALB/c mice rejected both B6.SJL and CBA/J skin grants. Mice
that received the double transplant (Figure 5) were grafted with
both B6.SJL and CBA/J skin grafts at 37.5 weeks after first marrow
infusion. One mouse was evaluated in group VII and 2 mice in
group VIII. All skin grafts were promptly rejected.
Discussion
The present results establish a unique model for creation of
nontoxic long-term stable high-level hematopoietic allochimerism.
We have shown that antigen preexposure with concomitant CD40/
CD40 ligand costimulator blockade allows for high levels of
chimerism with transplantation of 40 million H-2 mismatched
B6.SJL marrow to 100-cGy–treated BALB/c hosts. All compo-
nents of the protocol appear essential because omission of anti-
body, spleen cell infusions, or irradiation results in low or absent
levels of chimerism. The chimerism is long-term, over half the
mouse’s life span, and without evidence of GVHD. It is multilin-
eage and shows a dose-response curve with regard to antibody
dose. This dose-response result is of interest, especially given the
relatively high amounts of CD40 ligand antibody demonstrating a
clear dose response. This probably relates to the completeness of
the costimulator blockade. This may be particularly so with a
regimen including antigen (spleen cell) pre-exposure. Based on
transplantation of 40 million B6.SJL marrow cells to 100-cGy–
treated C57BL/6 hosts (a histocompatible combination) the chimer-
ism averaging 20% to 30% in B6.SJL to BALB/c hosts may be
close to maximal for this level of infused cells, although higher
levels of chimerism are seen when 40 million male BALB/c cells
are transplanted to 100-cGy–treated female BALB/c hosts. How-
ever, increasing the level of transplanted B6.SJL cells to 80 million
virtually doubled allochimerism and increasing the antibody level
to 3.2 mg/injection also increased the level of allochimerism. Thus
chimerism can be obtained with a low-dose radiation regimen and
with minimal toxicity. Although hamster immunoglobulin has been
reported to accelerate collagen-induced arthritis,51 it showed no
activity in inducing tolerance in our model.
In work by Markees and colleagues47,48 similar antigen-specific
costimulator blockade approaches with skin allografts were evalu-
ated with challenge skin grafts from the donor strain. Five mice
Figure 5. The effect of spleen cell preexposure on
B6.SJL engraftment into 0-cGy or 100-cGy anti-CD40
ligand mAb–treated BALB/c hosts. Male BALB/c hosts
either unirradiated (groups I-IV) or exposed to 100 cGy
(groups V-VIII) were infused with 40 million male B6.SJL
cells on day 0 and injected intraperitoneally with 1.6 mg
anti-CD40 ligand mAb on days 210, 27, 23, 0, and 13
(groups II-IV and VI-VIII) or given no anti-CD40 ligand
antibody (groups I and V). Spleen cell (SC) sensitization
was omitted in groups II and VI or given on day 27
(groups III and VII) or day 210 (groups IV and VIII). Data
are expressed as percentage (%) CD45.1 cells in periph-
eral blood out to 31 weeks after transplantation. There
were 5 transplanted mice per group initially. Between
weeks 12 and 13 all mice received an infusion of 40
million B6.SJL (sex-matched) marrow cells. Asterisks
indicate groups that had received a second marrow
transplant; W, weeks; L, ligand; D, day.
Table 1. Comparison of engraftment level in different organs at 50 weeks after transplantation
ID* Group BM† (%) PB (%) Spleen (%) Thymus (%)
BALB/c 0 0 0 0
B6.SJL 82.68 93.79 98.44 95.24
I1 0 cGy/40 3 106 0.3 0 0.16 0.21
I2 0 cGy/40 3 106 0.13 0 0 0
IV4 100 cGy/0.4 mg anti-CD40L mAb/40 3 106 12.45 24.4 34.54 21.49
IV5 100 cGy/0.4 mg anti-CD40L mAb/40 3 106 0 0 0 0
V1 100 cGy/0.8 mg anti-CD40L mAb/40 3 106 4.22 11.26 24.21 10.58
V2 100 cGy/0.8 mg anti-CD40L mAb/40 3 106 18.34 30.05 58.64 24.79
BM indicates bone marrow; PB, peripheral blood.
*Identification of individual mice in groups I, IV, and V from Figure 3.
†The lower numbers in the BM column are due to the fact that CD45.1 mAb does not react with erythroid precursors in the marrow.
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whose primary skin allograft had survived for over 125 days
showed variable results with the challenge grafts: one mouse
rejected the challenge graft but retained the primary graft, one
mouse accepted the challenge graft and maintained the primary
graft, whereas 3 mice rejected both the primary and challenge
grafts.47,48 Our initial studies with donor and third-party skin grafts
in mice maintaining their marrow allografts show tolerance to
donor skin grafts with rejection of the third-party skin grafts. Thus
these mice show antigen-specific tolerance to both the marrow and
late-skin H-2 mismatched allografts. Conversely, mice given a
second marrow transplant (Figure 5) and then a skin graft showed
prompt rejection of both donor and third-party skin grafts,
while maintaining their marrow grafts, presumably a form of
split tolerance.
Standard marrow transplantation approaches have used high-
dose ablative chemo/radio therapy for tumor killing to facilitate
engraftment and to remove immune barriers. These approaches
have an early treatment-related mortality and morbidity and still
run the risk of graft rejection or GVHD. Solid organ transplantation
has also required immediate and long-term immunosuppressive
therapy with attendant risks. A number of attempts have been made
to obtain allochimerism with less toxic/immunosuppressive therapy.
Ildstad and colleagues52-55 have used a variety of approaches to
lower WBI, including elimination of CD41 and CD81 host T cells,
cytoxan and antilymphocyte globulin treatment along with manipu-
lation of T-cell receptor–CD81 facilitator cells.56 Sykes and
Figure 6. The effect of cell dose on engraftment of B6.SJL marrow cells into
100-cGy–irradiated BALB/c mice subjected to spleen cell pre-exposure and
CD40 ligand blockade. BALB/c hosts irradiated with 100 cGy were infused with
varying levels of B6.SJL marrow cells after splenic presensitization (day 210, 10
million cells) and CD40 ligand antibody blockade (days 210, 27, 23, 0, and 13).
Results are expressed as percentage (%) engraftment (CD45.11 cells) 6 1 SEM
from 3 to 15 weeks after transplantation. There were 5 mice per group. There was a
significant trend toward increasing engraftment as the cell doses increased; for
weeks 3, 6, 9, 12, and 15 weeks P values were .01, .02, .12, .03, and .03, respectively,
although when analyzed independently with Wilcoxon rank order there was no
significant difference between the 80 and 120 million cell groups.
Figure 7. Engraftment of B6.SJL marrow cells into 100-cGy–irradiated, spleen
pretreated BALB/c hosts injected with higher levels of anti-CD40 ligand mAb.
BALB/c hosts were infused with 10 million B6.SJL spleen cells on day 210 and
administered 1.6 or 3.2 mg of anti-CD40 ligand (L) mAb on days 210, 27, 23, 0, and
13. As preparation for transplantation on day 0 BALB/c mice were exposed to 100
cGy WBI and infused with 40 million B6.SJL marrow cells. Engraftment of donor cells
was determined as percentage (%) CD45.1 cells in peripheral blood at 3 to 15 weeks
after transplantation. There were 5 mice per group.
Figure 8. Serum clearance of anti-CD40 ligand mAb. Hamster anti-CD40 ligand
mAb levels were determined by ELISA of serum at 3 to 38 weeks after last antibody
injection (1.6 mg/injection). Serum levels from the groups presented in Figure 6 are
shown. There were 5 mice per group through week 15; at week 38 there were 5 mice
in the 40 million group, 2 mice in the 80 million group, and 3 mice in the 120 million
group. Background values of 0 to 1.42 ng/mL were found in normal BALB/c mouse
serum. Zero indicates no detectable antibody at 38 weeks.













Normal BALB/c mice 0 NA — —
0 NA — —
0 NA — —
0 NA — —
0 NA — —
Standard protocol 46.1 8 1(.7 wk) —
(1.6 mg anti-CD40 37.9 8 1(.7 wk) —
ligand antibody) 40.9 8 1(.7 wk) —
33.3 9 1(.7 wk) —
35.6 9 1(.7 wk) —
26.7 39 1(.6 wk) —
30.3 39 1(.6 wk) —
31.3 39 1(.6 wk) —
27.6 43 1(.31 wk) —
31.5 43 1(23 wk)* —
Standard protocol or 0.1 8 — —
variants of standard 0.03 8 — —
protocol 0.33 39 — —
0 39 — —
0 43 — —
0 43 — —
Grafts transplanted on the dorsal surface with B6.SJL on the left and CBA/J on
the right side.
BMT indicates bone marrow transplant; NA, not applicable; —, rejection
(rejection was completed within 10-12 days of graft application); 1, accepted graft
(number of weeks in parentheses represents duration of graft after graft application).
* This mouse died at 56 weeks after marrow graft, 23 weeks after skin graft;
cause unknown.
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colleagues57 have achieved allochimerism without myelosuppres-
sive host conditioning, using a B10.A to B6 marrow transplant
model with depleting anti-CD4 and anti-CD8 mAbs, local thymic
irradiation, and a high dose (174 3 106) of major histocompatibility–
mismatched (B10.A) marrow cells divided over days 0 through 4.
These investigators, as noted above, recently used combined
costimulator blockade with a WBI dose of 300 cGy, a lower dose of
marrow, and no T-cell–depleting antibodies or thymic irradiation,
and obtained long-term stable hematopoietic chimerism. More
recently, using a congenic H-2 mismatched model (a less rigorous
transplant model than B6.SJL to BALB/c), 200 million marrow
cells into nonirradiated hosts with CD40 ligand mAb and CTLA4
Ig treatment, Wekerle and colleagues58 obtained low-level multilin-
eage chimerism in 9 of 14 transplanted mice out to 30 weeks. This
was similar to the levels of engraftment at 31 weeks demonstrated
in our delayed transplants with no irradiation and with or without
spleen cell pre-exposure presented in Figure 4 (groups II and IV).
These BALB/c mice received a total of 80 million B6.SJL cells.
Storb and colleagues, using posttransplantation immune suppression/
modulation with cyclosporine and mycophenolate mofetil in a
DLA identical canine transplant model, have also significantly
lowered the irradiation dose needed to obtain allochimerism.59
Reisner and colleagues60-63 have suggested that stem cells express-
ing class I and class II without costimulator expression may be
tolerizing and that high levels of purified stem cells may provide a
means of obtaining long-term tolerance. In a related vein, others
have suggested that various marrow cell populations could induce
specific tolerance to donor-type antigens either by exhibiting
specific suppression or inducing anergy of cytotoxic T-lymphocyte
progenitors. These subpopulations include “natural” suppressors64;
CD8 nonalloreactive T cells65; CD81, CD31, CD45 R1, Thy-11,
and TCR2 “facilitator” cells56; and CD21, CD81, CD161, DR2,
CD32, and CD382 cells.66
Thus, part of the effectiveness of our approach, using antigen-
specific preexposure combined with anti-CD40 ligand blockade,
high levels of marrow cells, and nonablative (100 cGy) host
treatment, may be the infusion of appropriate numbers of tolerizing
stem cells or tolerizing cells without stem cell potential. In
addition, Ferrara67 has described the phenomenon of “cytokine
storm” occurring with cytoablative therapy and potentially induc-
ing GVHD. Low-dose host treatment would minimize or eliminate
this potentially deleterious effect. Finally, costimulator blockade in
the context of antigen presentation is a specific approach for
inducing antigen-specific tolerance. Thus, the present approach
combines multiple elements that may induce tolerance or diminish
immune reactivity as presented in Table 3.
The model described here is both nontoxic and flexible. It
would appear that the percent donor chimerism can be altered by
altering the cell level infused or antibody level injected. In
unpublished studies (H.W., S.Z., F.M.S., P.J.Q.) we have shown
that 30% to 40% chimerism in Hbbth/Hbbth thalassemia mice68
corrects the anemia of these mice. Other studies have shown that
partial allochimerism in human thalassemia transplant potentially
leads to correction of the anemia.69,70 These data suggest that the
present approach might be used in humans to purposefully create
nontoxic partial allochimerism to correct the anemia in patients
with thalassemia or sickle cell anemia.69-71 This type of approach
using CD40 ligand mAb for a costimulator blockage might be
complicated by thromboembolic toxicity as recently observed in
both primates and humans.72,73 However, this has not been a
universal experience, and the specifics of the antibody preparation
rather than the CD40-CD40 ligand blockade may be the problem.72
Similar approaches will be of interest in the immune therapy of
cancer and in transplant for autoimmune diseases.
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